FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2985631013> ?p ?o ?g. }

• W2985631013 endingPage "5588" @default.
• W2985631013 startingPage "5588" @default.
• W2985631013 abstract "Background: Carfilzomib (Car), a second-generation proteasome inhibitor (PI), has been approved by the US Food and Drug Administration (FDA) as therapy for relapsed and /or refractory multiple myeloma (RRMM), either as a single agent or in combination with other agents. It has proven to be superior in many ways compared to the the first generation PI, bortezomib, both in terms of superior efficacy and neuropathy related adverse effect profile. Carfilzomib has lower rate of peripheral neuropathy. In this review, we gathered data from trials which studied Carfilzomib for newly diagnosed MM (NDMM). Carfilzomib based two and three drug combination as induction regimens for the management of NDMM is an emerging approach. Through this systematic review, we explore efficacy, adverse effect profile of Car based regimens for NDMM. Methods: Per PRISMA guidelines, a thorough database search was conducted on 06/24/2019 using the following search engines; PubMed, EMBASE, Cochrane library, Scopus, Web of Science, CINAHL, and Clinicaltrials.gov. We included all published trials that used carfilzomib as an induction agent in NDMM patients and had at least response rates after induction. Results: The total number of articles identified with initial search were 1131, out of which 19 articles met our selection / eligibility criteria (n=2286). The overall response rates (ORR) after induction therapy with carfilzomib based regimens was very impressive (range: 84.3% - 100%). Two drug combination using carfilzomib and dexamethasone (n=72) had an ORR of 90% and a greater than very good partial response rate (>VGPR) of 84%. Three drug combinations used for induction therapy included carfilzomib/dexamethasone with immunomodulators (n=391) and alkylating agents (n=308). The combination of carfilzomib/dexamethasone with lenalidomide (n=189, ORR: 97% - 98%, >VGPR: 69% - 98%) and thalidomide (n=202, ORR: 90% - 94%, >VGPR: 66% - 68%) showed the best response. Alkylating agents used in combination with carfilzomib were melphalan (n=98, ORR: 90% - 93%, >VGPR: 58% - 70%), cyclophosphamide (n=192, ORR: 87% - 95%, >VGPR: 39% - 71%) and bendamustine (n=18, ORR; 100%, >VGPR: 89%). Four drug combinations with carfilzomib used were daratumumab/lenalidomide/dexamethasone (n=22, ORR: 100%, >VGPR: 90%, 12m PFS: 95%) and cyclophosphamide / thalidomide / dexamethasone (n=64, ORR; 91%, >VGPR: 69%, 24m PFS: 76%). One trial directly compared carfilzomib/melphalan/dexamethasone (n=478, ORR: 84%, >VGPR: 61%, PFS: 22.3m) with bortezomib/melphalan/dexamethasone (n=477, ORR: 79%, >VGPR: 49%, PFS: 22.1m). Another trial compared the combination of carfilzomib / dexamethasone with lenalidomide (n=315) or cyclophosphamide (n=159) that showed similar ORR (97% vs 91%) though >VGPR rate was better with lenalidomide (75% vs 60%). Efficacy data including progression free survival (PFS) for carfilzomib based regimens is reported in table 1. Most common >grade 3 hematological adverse effects reported were anemia (2% - 35%), lymphopenia (5% - 76%), thrombocytopenia (4% - 28%) and neutropenia (1% - 38%). Most Common >grade 3 non-hematological adverse events included cardiac events (5% - 10%), respiratory disorders (8% - 16%), infections (2% - 9%), hypertension (6% - 17%), renal events (9% - 10%) and hyperglycemia (6% - 23%). (Table 1) Conclusion: The overall efficacy and favorable adverse effect profile of Carfilzomib-based induction regimens seem very promising for the treatment of NDMM. Car is now approved for weekly dosing which is convenient. Due to cardiovascular toxicity seen in upto 10% cases, Car should be used very judiciously in patients with cardiovascular risk factors and heart failure. Several ongoing phase 3 clinical trials are studying Carfilzomib in various combinations will help to establish foundation for future standard therapy as well as next phase of drug development through clinical trials. Disclosures Anwer: In-Cyte: Speakers Bureau; Seattle Genetics: Membership on an entity's Board of Directors or advisory committees." @default.
• W2985631013 created "2019-11-22" @default.
• W2985631013 creator A5005991606 @default.
• W2985631013 creator A5018306647 @default.
• W2985631013 creator A5021422578 @default.
• W2985631013 creator A5024977679 @default.
• W2985631013 creator A5030126059 @default.
• W2985631013 creator A5039637944 @default.
• W2985631013 creator A5041626144 @default.
• W2985631013 creator A5041827740 @default.
• W2985631013 creator A5044045619 @default.
• W2985631013 creator A5049225871 @default.
• W2985631013 creator A5053420781 @default.
• W2985631013 creator A5054948609 @default.
• W2985631013 creator A5077206108 @default.
• W2985631013 creator A5089590392 @default.
• W2985631013 date "2019-11-13" @default.
• W2985631013 modified "2023-10-16" @default.
• W2985631013 title "Carfilzomib Based Regimens for Treatment of Newly Diagnosed Multiple Myeloma: A Systematic Review" @default.
• W2985631013 doi "https://doi.org/10.1182/blood-2019-128833" @default.
• W2985631013 hasPublicationYear "2019" @default.
• W2985631013 type Work @default.
• W2985631013 sameAs 2985631013 @default.
• W2985631013 citedByCount "0" @default.
• W2985631013 crossrefType "journal-article" @default.
• W2985631013 hasAuthorship W2985631013A5005991606 @default.
• W2985631013 hasAuthorship W2985631013A5018306647 @default.
• W2985631013 hasAuthorship W2985631013A5021422578 @default.
• W2985631013 hasAuthorship W2985631013A5024977679 @default.
• W2985631013 hasAuthorship W2985631013A5030126059 @default.
• W2985631013 hasAuthorship W2985631013A5039637944 @default.
• W2985631013 hasAuthorship W2985631013A5041626144 @default.
• W2985631013 hasAuthorship W2985631013A5041827740 @default.
• W2985631013 hasAuthorship W2985631013A5044045619 @default.
• W2985631013 hasAuthorship W2985631013A5049225871 @default.
• W2985631013 hasAuthorship W2985631013A5053420781 @default.
• W2985631013 hasAuthorship W2985631013A5054948609 @default.
• W2985631013 hasAuthorship W2985631013A5077206108 @default.
• W2985631013 hasAuthorship W2985631013A5089590392 @default.
• W2985631013 hasBestOaLocation W29856310131 @default.
• W2985631013 hasConcept C126322002 @default.
• W2985631013 hasConcept C143998085 @default.
• W2985631013 hasConcept C177713679 @default.
• W2985631013 hasConcept C197934379 @default.
• W2985631013 hasConcept C2776364478 @default.
• W2985631013 hasConcept C2777478702 @default.
• W2985631013 hasConcept C2778367456 @default.
• W2985631013 hasConcept C2780108899 @default.
• W2985631013 hasConcept C71924100 @default.
• W2985631013 hasConcept C98274493 @default.
• W2985631013 hasConceptScore W2985631013C126322002 @default.
• W2985631013 hasConceptScore W2985631013C143998085 @default.
• W2985631013 hasConceptScore W2985631013C177713679 @default.
• W2985631013 hasConceptScore W2985631013C197934379 @default.
• W2985631013 hasConceptScore W2985631013C2776364478 @default.
• W2985631013 hasConceptScore W2985631013C2777478702 @default.
• W2985631013 hasConceptScore W2985631013C2778367456 @default.
• W2985631013 hasConceptScore W2985631013C2780108899 @default.
• W2985631013 hasConceptScore W2985631013C71924100 @default.
• W2985631013 hasConceptScore W2985631013C98274493 @default.
• W2985631013 hasIssue "Supplement_1" @default.
• W2985631013 hasLocation W29856310131 @default.
• W2985631013 hasOpenAccess W2985631013 @default.
• W2985631013 hasPrimaryLocation W29856310131 @default.
• W2985631013 hasRelatedWork W155247308 @default.
• W2985631013 hasRelatedWork W1850271161 @default.
• W2985631013 hasRelatedWork W2061032583 @default.
• W2985631013 hasRelatedWork W2063424779 @default.
• W2985631013 hasRelatedWork W2269989009 @default.
• W2985631013 hasRelatedWork W2394791231 @default.
• W2985631013 hasRelatedWork W2400769328 @default.
• W2985631013 hasRelatedWork W2521212135 @default.
• W2985631013 hasRelatedWork W2783534173 @default.
• W2985631013 hasRelatedWork W3184357652 @default.
• W2985631013 hasVolume "134" @default.
• W2985631013 isParatext "false" @default.
• W2985631013 isRetracted "false" @default.
• W2985631013 magId "2985631013" @default.
• W2985631013 workType "article" @default.